8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 20, 2008

MEDTOX SCIENTIFIC, INC.

(Exact name of registrant as specified in its charter)

Delaware	1-11394	95-3863205
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

402 West County Road D, St. Paul, Minnesota	55112
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (651) 636-7466

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

1

Item 7.01. Regulation FD Disclosure

On May 20, 2008, MEDTOX Scientific, Inc. held its Annual Meeting of Stockholders. The presentation to stockholders is attached as Exhibit 99.1.

Item 8.01. Other Events

On May 20, 2008, MEDTOX Scientific, Inc. held its Annual Meeting of Stockholders. Stockholders elected one incumbent director, Richard J. Braun, MBA, JD, to a three-year term expiring in 2011. Mr. Braun joins Brian P. Johnson, MBA, Robert J. Marzec, MBA, CPA, Samuel C. Powell, Ph.D. and Robert A. Rudell, MBA, whose terms expire in 2009 and 2010, as directors on the MEDTOX five-member board of directors.

In addition, stockholders approved a proposal to ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2008.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits.

The following exhibits are filed as part of this report:

ExhibitNo.	Description
99.1	MEDTOX Scientific, Inc. presentation to stockholders, dated May 20, 2008.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDTOX Scientific, Inc.

Date: May 27, 2008 By: /s/ Richard J. Braun

Name: Richard J. Braun

Title: Chief Executive Officer

3

INDEX TO EXHIBITS

ExhibitNo.	Description
99.1	MEDTOX Scientific, Inc. presentation to stockholders, dated May 20, 2008.

4

EX-99

2008 Annual
Stockholders Meeting

May 20, 2008

Financial Highlights

0.52

0.75

Diluted Earnings Per Share

4,548

6,690

Net Income

8,201

10,016

Income from Operations

      31,005

36,356

Gross Profit

      
$69,804

$80,285

Revenues

2006

2007

in thousands, except for per share
amounts

Revenue Growth

Compound average growth rate 12%

Gross Margin

Operating Margin

Operating Income

Diluted Earnings Per Share

Cash Flows

Financial Ratios

Period Ending:

12/31/2007

12/31/2006

12/31/2005

12/31/2004

12/31/2003

Current Ratio

197%

210%

196%

124%

111%

Quick Ratio

163%

156%

144%

83%

75%

Cash Ratio

19%

14%

15%

2%

5%

Pre-Tax Margin

12%

10%

7%

5%

-1%

Profit Margin

8%

7%

5%

3%

-1%

Pre-Tax ROE

17%

15%

9%

8%

-1%

After Tax ROE

12%

9%

7%

5%

-1%

Operating Expenses as a  

Percent of Sales

32.8%

32.7%

34.3%

34.4%

36.2%

Liquidity Ratios

Profitability Ratios

MEDTOX Scientific, Inc.

Building For The Future!

Background

MEDTOX: Drug TestingIndustry Leader

Late 1990’s:

Began developing Clinical Lab capabilities

Early 2000’s:

Introduced Clinical Trial Services

2007:

Continued Clinical Laboratory expansion

MEDTOX Total Revenue

Areasof ClinicalExpansion

Areas of Clinical Expansion

Regional Clinical Laboratory

Offering lab services for physician market

Accessible regional market = $200 MM+ revenue

Areas of laboratory specialty

Anatomic Pathology & Cytology

Microbiology

Molecular diagnostics

Comprehensive clinical chemistry

Hematology

Immunology

Areas of Clinical Expansion

Pain Management

70 MM+ Americans suffer from chronic pain

Management of pain is a growing industry

ToxAssure^® Program: Pain Patient Monitoring

Targeted Market Segments

Pain clinics

Hospitals

Family practice

Other medical practices

Areas of Clinical Expansion

Clinical Trials Services

Current Areas of Focus

Bio-Analytical Services & Assay Development

Central Laboratory Services

New Opportunities – New Clinical Laboratory

Flow Cytometry

Anatomic Pathology/Cytology

Molecular Diagnostics/Pathology

Microbiology

Expanded Biomarkers

Shareholder Benefits

Exciting new revenue opportunities

Continued laboratory diversification

Less exposure to economic downturns

Platform to participate in new clinical areas

Expanded capabilities extend to multiple
markets

RCL scalable to new geographic markets

2008 Annual
Stockholders Meeting

May 20, 2008